Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.

Peiró I, Palmero R, Iglesias P, Díez JJ, Simó-Servat A, Marín JA, Jiménez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C.

Endocrine. 2019 Jun;64(3):605-613. doi: 10.1007/s12020-019-01871-7. Epub 2019 Feb 25.

PMID:
30805887
2.

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.

Bergamino M, Rullan AJ, Saigí M, Peiró I, Montanya E, Palmero R, Ruffinelli JC, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Cardenal F, Nadal E.

BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5.

3.

Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E.

Autoimmun Rev. 2018 Oct;17(10):1040-1045. doi: 10.1016/j.autrev.2018.05.002. Epub 2018 Aug 10. Review.

PMID:
30103042
4.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

5.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR.

Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.

PMID:
29767677
6.

Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.

Antonio M, Saldaña J, Linares J, Ruffinelli JC, Palmero R, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Navarro V, González-Barboteo J, Borràs JM, Cardenal F, Nadal E.

Br J Cancer. 2018 Mar 6;118(5):639-647. doi: 10.1038/bjc.2017.455. Epub 2018 Jan 30.

7.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629
8.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
9.

Treatment of resectable stage IIIA non-small cell lung cancer.

Cardenal F, Palmero R.

J Thorac Dis. 2017 Jan;9(1):13-15. doi: 10.21037/jtd.2017.01.08. No abstract available.

10.

Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy.

Velasco R, Santos C, Soler G, Gil-Gil M, Pernas S, Galan M, Palmero R, Bruna J.

J Peripher Nerv Syst. 2016 Sep;21(3):134-41. doi: 10.1111/jns.12177.

PMID:
27282616
11.

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors.

Rosell R, Palmero R.

Cancer Biol Med. 2015 Jun;12(2):71-3. doi: 10.7497/j.issn.2095-3941.2015.0026. No abstract available.

12.

Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.

Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, Bernet L, Majem M, Bosch-Barrera J, Porta R, Alonso N, Palmero R, Taus A, Albanell J, Espinet B, Salido M, Arriola E.

J Thorac Oncol. 2014 Dec;9(12):1816-20. doi: 10.1097/JTO.0000000000000361.

13.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
14.

Fructose malabsorption in children with functional digestive disorders.

Lozinsky AC, Boé C, Palmero R, Fagundes-Neto U.

Arq Gastroenterol. 2013 Jul-Sep;50(3):226-30. doi: 10.1590/S0004-28032013000200040.

15.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
16.

Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.

Cardenal F, Arnaiz MD, Morán T, Jové J, Nadal E, Porta R, Solé JM, Brao I, Palmero R, Fuentes R, Núñez I, Caveda E, Cassinello A.

Lung Cancer. 2011 Oct;74(1):69-74. doi: 10.1016/j.lungcan.2011.01.021. Epub 2011 Feb 24.

PMID:
21353323
17.

Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.

Mesía R, Palmero R, Cos M, Vilajosana E, Vázquez S.

Head Neck Oncol. 2010 Jan 27;2:3. doi: 10.1186/1758-3284-2-3.

18.

Screening for epidermal growth factor receptor mutations in lung cancer.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group.

N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.

19.

Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.

Grau JJ, Monzó M, Caballero M, Carles J, Palmero R, Artells R, Pico C, Gascon P.

Acta Otolaryngol. 2007 Jan;127(1):71-5.

PMID:
17364333
20.

Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy.

Grau JJ, Palmero R, Marmol M, Domingo-Domenech J, Monzo M, Fuster J, Vidal O, Fondevila C, Garcia-Valdecasas JC.

World J Surg Oncol. 2006 Aug 11;4:53.

Supplemental Content

Loading ...
Support Center